February 19, 2018
TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
February 13, 2018
A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
February 6, 2018
TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.